2. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

LXR beta

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10627A
    GW3965 hydrochloride
    25+ Cited Publications

    		 LXR Cardiovascular Disease Cancer
    GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965 hydrochloride
  • HY-10629
    LXR-623
    10+ Cited Publications

    WAY 252623

    		 LXR Metabolic Disease Cancer
    LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
    LXR-623
  • HY-10627
    GW3965
    25+ Cited Publications

    		 LXR Cardiovascular Disease
    GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965
  • HY-108688
    GSK2033
    Maximum Cited Publications
    34 Publications Verification

    		 LXR Metabolic Disease
    GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
    GSK2033
  • HY-19919
    BMS-779788
    1 Publications Verification

    EXEL04286652; XL-652; BMS-788

    		 LXR Metabolic Disease
    BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.
    BMS-779788
  • HY-112813
    TUG-1375
    4 Publications Verification

    		 Free Fatty Acid Receptor Metabolic Disease
    TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pKi of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .
    TUG-1375
  • HY-18282
    AZ876

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
    AZ876
  • HY-W014589
    2,4-Di-tert-butylphenol
    2 Publications Verification

    2,4-DTBP

    		 Endogenous Metabolite Fungal Apoptosis RAR/RXR Amyloid-β Infection Neurological Disease Inflammation/Immunology Cancer
    2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities and has the potential to inhibit Aβ-induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of drugs and fragrances .
    2,4-Di-tert-butylphenol
  • HY-101442
    SR9238
    2 Publications Verification

    		 LXR Metabolic Disease
    SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238
  • HY-144549
    LXR agonist 1

    		LXR Cardiovascular Disease
    LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis .
    LXR agonist 1
  • HY-101973
    XL041

    BMS-852927

    		 LXR Cardiovascular Disease
    XL041 (BMS-852927) is an LXRβ-selective agonist.
    XL041
  • HY-123148
    IMB-808

    		LXR Inflammation/Immunology
    IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used for the study of atherosclerosis research .
    IMB-808
  • HY-W002314
    2-Bromo-4'-hydroxyacetophenone

    		Environmental Pollutants Drug Intermediate Phosphatase Cardiovascular Disease
    2-Bromo-4'-hydroxyacetophenone is a PTP1B inhibitor with a Ki value of 42 μM. 2-Bromo-4'-hydroxyacetophenone is also an intermediate. 2-Bromo-4'-hydroxyacetophenone can be used in the synthesis of LXRα/β antagonists. 2-Bromo-4'-hydroxyacetophenone can be used in research on hematological diseases .
    2-Bromo-4'-hydroxyacetophenone
  • HY-N2509
    Iristectorigenin B

    Iristectrigenin B

    		 LXR Cardiovascular Disease
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .
    Iristectorigenin B
  • HY-123402
    GSK3987
    2 Publications Verification

    		 LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation .
    GSK3987
  • HY-77278
    25-Hydroxytachysterol3

    		VD/VDR Aryl Hydrocarbon Receptor LXR PPAR Others
    25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .
    25-Hydroxytachysterol3
  • HY-P5189A
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA

    		Endogenous Metabolite Cholinesterase (ChE) Others
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA
  • HY-100469
    LXRβ agonist-2

    		LXR Inflammation/Immunology
    LXRβ agonist-2 is an orally active and selective LXRβ agonist. LXRβ agonist-2 increases high-density lipoprotein cholesterol levels without elevating plasma triglyceride levels. LXRβ agonist-2 decreases lipid accumulation area in the aortic arch. LXRβ agonist-2 can be used for the research of atherosclerosis .
    LXRβ agonist-2
  • HY-160038
    GAC0003A4

    		LXR Cancer
    GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies .
    GAC0003A4
  • HY-W014589R
    2,4-Di-tert-butylphenol (Standard)

    2,4-DTBP (Standard)

    		 Reference Standards Endogenous Metabolite Fungal Apoptosis RAR/RXR Amyloid-β Infection Neurological Disease Inflammation/Immunology Cancer
    2,4-Di-tert-butylphenol (Standard) is the analytical standard of 2,4-Di-tert-butylphenol (HY-W014589). This product is intended for research and analytical applications. 2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities, and has the potential to inhibit Aβ-induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of pharmaceuticals and fragrances .
    2,4-Di-tert-butylphenol (Standard)
  • HY-W749327
    2,4-Di-tert-butylphenol-d21

    2,4-DTBP-d21

    		 Isotope-Labeled Compounds RAR/RXR Amyloid-β Fungal Apoptosis Endogenous Metabolite Infection Neurological Disease Inflammation/Immunology Cancer
    2,4-Di-tert-butylphenol-d21 (2,4-DTBP-d21) is the deuterium labeled 2,4-Di-tert-butylphenol (HY-W014589). 2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities and has the potential to inhibit Aβ-induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of drugs and fragrances .
    2,4-Di-tert-butylphenol-d21
  • HY-D1734
    FITC-GW3965

    		LXR Cardiovascular Disease
    FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ .
    FITC-GW3965
  • HY-33821
    LXRβ ligand 1

    		LXR Others
    LXRβ ligand 1 is a LXR β ligand-binding domain agonist, with an EC50 of 57 μM and a Ki of 28 μM against human LXR β. LXRβ ligand 1 forms hydrogen bonds with His435, stabilizes the His-Trp activation switch, and locks the ligand-binding domain in an agonist conformation; its tert-butyl moiety occupies a hydrophobic subpocket, while its phenyl moiety forms a π-π stacking interaction with Phe329. LXRβ ligand 1 serves as a structural unit for the development of LXRβ modulators .
    LXRβ ligand 1
  • HY-143259
    BE1218

    		LXR Cancer
    BE1218 is a liver X receptor (LXR) inverse agonist with IC50 values of 9 nM and 7 nM against LXRα and LXRβ, respectively .
    BE1218
  • HY-133830
    7α,24(S)-Dihydroxycholesterol

    (3β,7α,24S)-Cholest-5-ene-3,7,24-triol

    		 Endogenous Metabolite Others
    7α,24(S)-Dihydroxycholesterol ((3β,7α,24S)-Cholest-5-ene-3,7,24-triol) serves as a ligand for liver X receptor (LXR), binding specifically to the ligand binding domains of both LXRα and LXRβ. This compound is synthetically produced from E-α,β-enone, utilizing Arsonium ylide and J-tert-butyldimethylsilyloxy-bisnor-5-cholenaldehyde as starting materials, followed by a series of transformations to yield 7α,24(S)-dihydroxycholesterol.
    7α,24(S)-Dihydroxycholesterol
  • HY-146275
    LXRβ agonist-3

    		LXR Cancer
    LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .
    LXRβ agonist-3
  • HY-179278
    LXR agonist 4

    		LXR Cardiovascular Disease Metabolic Disease Endocrinology
    LXR agonist 4 is a selective LXR inverse agonist with IC50 values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) .
    LXR agonist 4
  • HY-N2273
    Gymnestrogenin

    		LXR Metabolic Disease
    Gymnestrogenin is a pentahydroxytriterpene from the leaves of Gymnema sylvestre R.Br . Gymnestrogenin is a LXR antagonist with IC50s of 2.5 and 1.4 μM for LXRα and LXRβ transactivation, respectively. Gymnestrogenin reduces the transcriptional activity of LXR even on its own promoter, thus reducing the mRNA expression .
    Gymnestrogenin
  • HY-170570
    PFM046

    		LXR Stearoyl-CoA Desaturase (SCD) Fatty Acid Synthase (FASN) Cancer
    PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC50 of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models .
    PFM046
  • HY-185104
    Ginsenoside C-K hexapropionate ester

    		LXR Cardiovascular Disease
    Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride .
    Ginsenoside C-K hexapropionate ester
  • HY-18282R
    AZ876 (Standard)

    		LXR Cardiovascular Disease Metabolic Disease Cancer
    AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
    AZ876 (Standard)
  • HY-10629R
    LXR-623 (Standard)

    WAY 252623 (Standard)

    		 Reference Standards LXR Metabolic Disease Cancer
    LXR-623 (Standard) is the analytical standard of LXR-623. This product is intended for research and analytical applications. LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
    LXR-623 (Standard)
  • HY-RS26222
    Nr1h2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nr1h2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nr1h2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nr1h2 Rat Pre-designed siRNA Set A
    Nr1h2 Rat Pre-designed siRNA Set A
  • HY-173393
    LXRα agonist 1

    		LXR Cancer
    LXRα agonist 1 (Compound 40) is a selective LXRα agonist (EC50: 42 nM). LXRα agonist 1 also has a certain agonistic effect on LXRβ (EC50: 266 nM). LXRα agonist 1 promotes target gene transcription by stabilizing the ligand binding domain (LBD) of LXRα. LXRα agonist 1 exhibits potent antitumor effects in hepatocellular carcinoma cells when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the study of lipotoxic cancers .
    LXRα agonist 1
  • HY-101442R
    SR9238 (Standard)

    		Reference Standards LXR Metabolic Disease
    SR9238 (Standard) is the analytical standard of SR9238. This product is intended for research and analytical applications. SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238 (Standard)
  • HY-14353
    GSK-9772

    		LXR Neurological Disease Inflammation/Immunology
    GSK-9772 is a Liver X Receptor (LXR) modulator of the N-phenyl tertiary amine class (NPTAs) with high affinity for LXR β ligand (IC50=30 nM). GSK-9772 has anti-inflammatory activity by binding to LXR, specifically by interacting with the region associated with the transcriptional repression function of the receptor, thereby inhibiting the expression of pro-inflammatory genes. GSK-9772 can be used in the study of inflammatory and neurodegenerative diseases .
    GSK-9772
  • HY-10627AR
    GW3965 hydrochloride (Standard)

    		Reference Standards LXR Cardiovascular Disease Cancer
    GW3965 (hydrochloride) (Standard) is the analytical standard of GW3965 (hydrochloride). This product is intended for research and analytical applications. GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965 hydrochloride (Standard)
  • HY-121671
    TBTC

    		RAR/RXR Neurological Disease
    TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models .
    TBTC
  • HY-177890
    UAB116

    		LXR RAR/RXR Wnt β-catenin Cancer
    UAB116 is a Liver X Receptor (LXR)/Retinoid X Receptor (RXR) agonist. UAB116 can decreases metastatic phenotype in hepatoblastoma by inhibiting the Wnt/β-Catenin pathway via upregulation of TRIM29. UAB116 can reduce proliferation, stemness and invasiveness of metastatic hepatoblastoma cells .
    UAB116
  • HY-115780
    E17110

    		LXR ATP-binding cassette (ABC) transporters Cardiovascular Disease
    E17110 is a liver X receptor β (LXRβ) agonist with an EC50 of 0.72 μM. E17110 can increase the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 macrophages. E17110 also reduce cellular lipid accumulation and promoted cholesterol efflux. E17110 can be used for the research of cardiovascular disease, such as atherosclerosis .
    E17110
  • HY-178959
    FXR agonist 13

    		FXR Metabolic Disease Inflammation/Immunology
    FXR agonist 13 is a selective, orally active, potent FXR agonist (EC50 = 0.097 μM) and has favorable hepatic microsomal metabolic stability. FXR agonist 13 exhibits moderate affinity for FXR-LBD upon direct binding (KD = 14.74 μM). FXR agonist 13 displays good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. FXR agonist 13 can be used for the study of metabolic-associated steatohepatitis (MASH) .
    FXR agonist 13
  • HY-W014589S
    2,4-Di-tert-butylphenol-d19

    2,4-DTBP-d19

    		 Isotope-Labeled Compounds RAR/RXR Amyloid-β Fungal Apoptosis Endogenous Metabolite Infection Neurological Disease Inflammation/Immunology Cancer
    2,4-Di-tert-butylphenol-d19 (2,4-DTBP-d19) is the deuterium labeled 2,4-Di-tert-butylphenol (HY-W014589). 2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities and has the potential to inhibit Aβ-induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of drugs and fragrances .
    2,4-Di-tert-butylphenol-d19
  • HY-108688R
    GSK2033 (Standard)

    		Reference Standards LXR Metabolic Disease
    GSK2033 (Standard) is the analytical standard of GSK2033 (HY-108688). This product is intended for research and analytical applications. GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα or LXRβ, respectively.
    GSK2033 (Standard)
  • HY-181226
    LXR modulator-1

    		LXR Metabolic Disease
    LXR modulator-1 (Compound 21/3) is a LXR modulator with an EC50 of less than 100 nM. LXR modulator-1 can be used for studying LXR-mediated diseases such as non-alcoholic fatty liver disease .
    LXR modulator-1
  • HY-182014
    TLC-2716

    		LXR Cardiovascular Disease Metabolic Disease
    TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
    TLC-2716
  • HY-10627R
    GW3965 (Standard)

    		Reference Standards LXR Cardiovascular Disease
    GW3965 (Standard) is the analytical standard of GW3965 (HY-10627). This product is intended for research and analytical applications. GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .
    GW3965 (Standard)
  • HY-RS19726
    Nr1h2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nr1h2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nr1h2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nr1h2 Mouse Pre-designed siRNA Set A
    Nr1h2 Mouse Pre-designed siRNA Set A
  • HY-179703
    FXR agonist 15

    		FXR Inflammation/Immunology
    FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC50 of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC50 values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH) .
    FXR agonist 15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: